Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| Online-Ressource |
Verfasst von: | Aigner, Julia [VerfasserIn]  |
| Marmé, Frederik [VerfasserIn]  |
| Smetanay, Katharina [VerfasserIn]  |
| Schütz, Florian [VerfasserIn]  |
| Jäger, Dirk [VerfasserIn]  |
| Schneeweiss, Andreas [VerfasserIn]  |
Titel: | Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice |
Verf.angabe: | Julia Aigner, Frederik Marmé, Katharina Smetanay, Florian Schuetz, Dirk Jaeger and Andreas Schneeweiss |
E-Jahr: | 2013 |
Jahr: | August 2013 |
Umfang: | 7 S. |
Teil: | volume:33 |
| year:2013 |
| number:8 |
| month:08 |
| pages:3407-3413 |
| extent:7 |
Fussnoten: | Gesehen am 07.05.2021 |
Titel Quelle: | Enthalten in: Anticancer research |
Ort Quelle: | Attiki, 2004 |
Jahr Quelle: | 2013 |
Band/Heft Quelle: | 33(2013), 8 vom: Aug., Seite 3407-3413 |
ISSN Quelle: | 1791-7530 |
Abstract: | Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m2. Results: Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia. Conclusion: According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials. |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://ar.iiarjournals.org/content/33/8/3407 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | chemotherapy |
| Metastatic breast cancer |
| nab-paclitaxel |
K10plus-PPN: | 1757479465 |
Verknüpfungen: | → Zeitschrift |
Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice / Aigner, Julia [VerfasserIn]; August 2013 (Online-Ressource)
68735211